IONS IONIS PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, IONIS PHARMACEUTICALS INC reported revenue of $268M (down 40.7% from a year earlier), net income of −$115M and diluted EPS of −$0.69; over the last four quarters revenue was $874M and net income −$565M; for the fiscal year ended December 2025 revenue was $944M, up 33.8% on the year before.

IONS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $944M, gross profit n/a, operating income −$382M, net income −$381M (margin -40.4%), EPS −$2.38
• Fiscal year ended Dec 2024: revenue $705M, gross profit n/a, operating income −$475M, net income −$454M (margin -64.4%), EPS −$3.04
• Fiscal year ended Dec 2023: revenue $788M, gross profit n/a, operating income −$354M, net income −$366M (margin -46.5%), EPS −$2.56
• Fiscal year ended Dec 2022: revenue $587M, gross profit n/a, operating income −$410M, net income −$270M (margin -45.9%), EPS −$1.90
• Fiscal year ended Dec 2021: revenue $810M, gross profit n/a, operating income −$30.2M, net income −$28.6M (margin -3.5%), EPS −$0.20

IONS quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $268M (down 40.7% year over year), net income −$115M, EPS −$0.69
• Quarter ended Mar 31, 2026: revenue $246M (up 87.0% year over year), net income −$92.5M, EPS −$0.56
• Quarter ended Dec 31, 2025: revenue $203M (down 10.3% year over year), net income −$229M, EPS −$1.41
• Quarter ended Sep 30, 2025: revenue $157M (up 17.1% year over year), net income −$129M, EPS −$0.80
• Quarter ended Jun 30, 2025: revenue $452M (up 100.7% year over year), net income $124M, EPS $0.70
• Quarter ended Mar 31, 2025: revenue $132M (up 10.1% year over year), net income −$147M, EPS −$0.93
• Quarter ended Dec 31, 2024: revenue $227M (down 30.2% year over year), net income −$104M, EPS −$0.66
• Quarter ended Sep 30, 2024: revenue $134M (down 7.2% year over year), net income −$140M, EPS −$0.95
• Quarter ended Jun 30, 2024: revenue $225M (up 19.6% year over year), net income −$66.3M, EPS −$0.45
• Quarter ended Mar 31, 2024: revenue $119M (down 8.4% year over year), net income −$143M, EPS −$0.98
• Quarter ended Dec 31, 2023: revenue $325M (up 113.6% year over year), net income −$9.26M, EPS −$0.06
• Quarter ended Sep 30, 2023: revenue $144M (down 9.7% year over year), net income −$147M, EPS −$1.03
• Quarter ended Jun 30, 2023: revenue $188M (up 40.8% year over year), net income −$85.3M, EPS −$0.60
• Quarter ended Mar 31, 2023: revenue $131M (down 8.0% year over year), net income −$124M, EPS −$0.87
• Quarter ended Dec 31, 2022: revenue $152M (down 65.5% year over year), net income −$52.4M, EPS −$0.37
• Quarter ended Sep 30, 2022: revenue $160M (up 20.0% year over year), net income −$47.0M, EPS −$0.33
• Quarter ended Jun 30, 2022: revenue $134M (up 6.4% year over year), net income −$105M, EPS −$0.74
• Quarter ended Mar 31, 2022: revenue $142M (up 27.2% year over year), net income −$65.2M, EPS −$0.46
• Quarter ended Dec 31, 2021: revenue $440M, net income $225M, EPS $1.41
• Quarter ended Sep 30, 2021: revenue $133M, net income −$82.5M, EPS −$0.58

IONS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$269M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$501M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$308M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$274M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $30.8M, share buybacks $0

IONS balance sheet

• Jun 30, 2026: cash $350M, total assets $2.99B, total liabilities $2.55B, shareholders' equity $440M
• Mar 31, 2026: cash $173M, total assets $3.45B, total liabilities $2.96B, shareholders' equity $491M
• Dec 31, 2025: cash $372M, total assets $3.52B, total liabilities $3.03B, shareholders' equity $489M, long-term debt $1.33B
• Sep 30, 2025: cash $338M, total assets $3.03B, total liabilities $2.42B, shareholders' equity $618M
• Jun 30, 2025: cash $297M, total assets $2.99B, total liabilities $2.35B, shareholders' equity $632M
• Mar 31, 2025: cash $264M, total assets $2.81B, total liabilities $2.34B, shareholders' equity $476M
• Dec 31, 2024: cash $242M, total assets $3.00B, total liabilities $2.42B, shareholders' equity $588M, long-term debt $1.20B
• Sep 30, 2024: cash $335M, total assets $3.08B, total liabilities $2.42B, shareholders' equity $662M

What is IONS's revenue?

IONIS PHARMACEUTICALS INC reported $874M of revenue over its last four quarters, through June 30, 2026.

Is IONS profitable?

No. IONIS PHARMACEUTICALS INC lost $565M over the last four quarters.

What is IONS's EPS?

Diluted earnings per share over the last four quarters were −$3.46; −$0.69 in the latest quarter.

IONS ownership and insider trades · All stocks